Hemoperfusion Market Size, Share, Growth, And Industry Analysis By Type (Activated Carbon Adsorption, Resin Adsorption) By Application (Hepatic Encephalopathy, Certain Autoimmune Diseases, Drug Overdose, Specific Intoxications & Others), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

HEMOPERFUSION MARKET OVERVIEW

The global hemoperfusion market is anticipated to witness consistent growth, starting at USD 0.99 billion in 2025, reaching USD 1.17 billion in 2026, and climbing to USD 5.21 billion by 2035, with a steady CAGR of 18.1% from 2025 to 2035. 

Hemoperfusion is a medical procedure that involves the removal of toxins or unwanted substances from the bloodstream. It is performed by passing the patient's blood through a specialized device called a hemoperfusion cartridge or column, which contains adsorbent materials that can selectively bind and remove certain substances. This process is commonly used in cases of acute poisoning, drug overdoses, and in some cases, certain medical conditions. Hemoperfusion can help rapidly reduce toxin levels and improve the patient's overall condition. However, its use is limited to specific situations and is typically employed alongside other treatment modalities.

The hemoperfusion market size is experiencing growth due to several factors driving increased demand for this medical procedure. As advancements in medical technology continue, hemoperfusion has become more efficient, safer, and accessible, attracting both healthcare providers and patients. Additionally, the rising incidence of drug overdoses, environmental toxin exposure, and acute poisonings has underscored the crucial role of hemoperfusion in rapidly removing harmful substances from the bloodstream. Moreover, the procedure's effectiveness as an adjuvant therapy for certain medical conditions has garnered attention, further contributing to its expanding market size as healthcare professionals recognize its potential benefits.

KEY FINDINGS

COVID-19 IMPACT

The Pandemic Spurred Further Research And Development Work, Which Led To Enhanced Procedures And Technology For Hemoperfusion

The COVID-19 pandemic has been unprecedented and staggering, with hemoperfusion market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic has had a notable impact on the hemoperfusion market. As healthcare systems worldwide grappled with the virus's severe respiratory and systemic effects, the demand for advanced treatment modalities like hemoperfusion rose. The virus's ability to cause cytokine storms and organ damage heightened the need for effective toxin removal and immune regulation, driving interest in hemoperfusion as a potential supportive therapy. Furthermore, the pandemic prompted increased research and development efforts, resulting in improved hemoperfusion technologies and protocols. While disruptions in supply chains and healthcare priorities initially posed challenges, the pandemic ultimately accelerated the adoption of hemoperfusion, leading to its broader recognition as a vital tool in managing critically ill patients. 

LATEST TRENDS

The Creation Of More Focused And Specialised Adsorbents For The Elimination Of Toxins Is One Significant Trend In The Hemoperfusion Industry

One prominent trend in the hemoperfusion market is the development of more specialized and targeted adsorbents for toxin removal. New products and technologies are emerging, focusing on enhancing the selectivity and efficiency of hemoperfusion. These advancements involve designing adsorbents with higher affinity for specific toxins, minimizing the impact on essential molecules, and improving overall treatment outcomes. Leading players in the market, such as Jafron Biomedical and Toray Industries, are actively investing in research and innovation to create novel adsorbent materials. Additionally, collaborations with academic institutions and research centers are fostering the exploration of cutting-edge techniques, paving the way for tailored hemoperfusion solutions that can address a wider range of toxins and medical conditions.

• According to clinical evaluations cited by the U.S. National Institutes of Health (NIH), hemoperfusion therapy using Jafron HA series cartridges demonstrated a 46% mortality rate in treated sepsis patients compared to 55% in controls, along with a measurable reduction in interleukin-6 and interleukin-8 levels and shorter ICU stays.

• As per findings referenced by the World Health Organization (WHO), HA330 and HA380 hemoperfusion cartridges have been utilized to reduce inflammatory mediators such as IL-6, IL-10, and TNF-α in patients with severe COVID-19, acute pancreatitis, and sepsis, resulting in improved organ function outcomes in more than 60% of observed cases.

Request a Free sample to learn more about this report

HEMOPERFUSION MARKET SEGMENTATION

By Type

Depending on hemoperfusion market given are types: activated carbon adsorption, resin adsorption. The activated carbon adsorption type will capture the maximum market share through 2035.

By Application

The market is divided into hepatic encephalopathy, certain autoimmune diseases, drug overdose, specific intoxications & others based on application. The global hemoperfusion market  players in cover segment like Hepatic Encephalopathy will dominate the market share during 2035.

DRIVING FACTORS

One Major Driver Propelling The Growth Of The Hemoperfusion Market Is The Rising Incidence Of Acute Poisonings And Drug Overdoses

A significant driving factor behind the hemoperfusion market growth is the increasing prevalence of acute poisonings and drug overdoses. As societal challenges related to substance abuse persist, the demand for rapid and effective toxin removal methods has surged. Hemoperfusion offers a targeted approach to swiftly eliminate harmful substances from the bloodstream, aiding in the stabilization and recovery of patients in critical condition. Healthcare professionals recognize its potential to save lives and mitigate long-term health consequences, which has led to wider adoption. Moreover, ongoing research and development efforts are refining hemoperfusion techniques, making the procedure more efficient and adaptable to various toxins, further propelling its market growth.

The Growing Use Of Hemoperfusion As An Adjuvant Therapy For A Variety Of Medical Disorders Is Another Key Reason Propelling The Market's Rise

Another driving factor contributing to the hemoperfusion market growth is its increasing application as an adjuvant therapy for various medical conditions. Clinical studies and research have shown promising results in using hemoperfusion to manage conditions such as sepsis, liver failure, and autoimmune diseases. This expanding scope of application has attracted the attention of healthcare providers and specialists, leading to greater adoption of hemoperfusion as a complementary treatment option. The potential to modulate immune responses, remove inflammatory mediators, and support organ function has sparked interest in integrating hemoperfusion into multidisciplinary treatment protocols, driving its market growth as a versatile and valuable therapeutic tool.

• According to WHO and Global Kidney Health reports, more than 850 million people globally are affected by kidney-related disorders, significantly increasing the use of extracorporeal blood purification technologies such as hemoperfusion in hospitals and intensive care units.

• As per data published by Jafron Biomedical in 2021, the company invested USD 27 million in research and development—an increase of 115% over the previous year—focused on enhancing hemoperfusion cartridge resin adsorption capacity and overall efficiency in critical care treatment.

RESTRAINING FACTOR

The Need For Specialised Equipment And Highly Trained Employees Is A Barrier To The Hemoperfusion Market's Expansion

A restraining factor impacting the hemoperfusion market growth is the requirement for specialized equipment and trained personnel. The setup and operation of hemoperfusion systems necessitate technical expertise, which could limit its widespread use, particularly in healthcare facilities with limited resources or in remote areas. The costs associated with acquiring and maintaining the necessary equipment, as well as training healthcare professionals, might pose challenges for broader adoption. Addressing these barriers through improved training programs, technological simplification, and cost-effective solutions will be crucial to overcoming this restraining factor and ensuring wider access to the benefits of hemoperfusion.

• According to analyses from the National Library of Medicine (NLM), while hemoperfusion has demonstrated potential clinical benefits, most randomized trials available are classified as having low or very low certainty evidence, which limits its widespread integration across clinical guidelines.

• As stated by the U.S. Food and Drug Administration (FDA), continuous renal replacement therapy (CRRT) and plasma exchange are already used in over 70% of intensive care units for cytokine and toxin removal, creating strong competition that restricts the expansion of hemoperfusion applications.

• Request a Free sample to learn more about this report

•  

HEMOPERFUSION MARKET REGIONAL INSIGHTS

The Asia-Pacific Region Is Positioned To Play A Crucial Role In The Hemoperfusion Market's Growth In The Near Future Due To Its Big And Diversified Population

The Asia-Pacific region stands out as a leading and dynamic market for hemoperfusion, poised for substantial growth of market share. With a rapidly evolving healthcare landscape and increasing awareness about advanced medical interventions, the region is witnessing a surge in the adoption of hemoperfusion technology. Factors such as the rising incidence of poisonings, greater access to healthcare facilities, and growing investments in medical research and infrastructure are propelling the demand. Moreover, the presence of key market players focusing on product development and strategic collaborations, coupled with the region's large and diverse population, positions the Asia-Pacific region as a pivotal driver of hemoperfusion market expansion in the foreseeable future.

North America emerges as the second-leading region in the hemoperfusion market. Its robust healthcare infrastructure, significant research and development activities, and advanced medical technology adoption contribute to its prominent position. The region's emphasis on innovation and clinical advancements fosters the integration of hemoperfusion as a vital therapeutic option. Moreover, the prevalence of poisonings, drug-related incidents, and acute medical conditions further drives the demand for hemoperfusion. Key players in North America continue to invest in refining hemoperfusion techniques and expanding its applications. These factors collectively underscore North America's significant role in shaping the global hemoperfusion market share landscape.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Jafron Biomedical: Jafron Biomedical operates a manufacturing facility covering 56,000 square meters, certified under ISO 13485 and China GMP standards. The company’s HA-series cartridges have been applied clinically in multiple countries, tested among 24 sepsis patients with observed reductions in cytokine levels and shorter ICU durations compared to control groups.

• Baxter (Gambro): Baxter, through its Gambro division, has integrated resin-based hemoperfusion cartridges into its extracorporeal therapy portfolio. According to company and healthcare association disclosures, Baxter currently offers over 50 clinical-grade extracorporeal systems operating in more than 100 countries, reinforcing its global leadership position in advanced blood purification technologies.

List of Top Hemoperfusion Companies 

• Jafron Biomedical (China)
• Baxter (Gambro) (U.S.)
• Asahi-Kasei (Japan)
• Biosun Medical (China)
• Kaneka (Japan)
• Toray Medical (Japan)
• Cytosorbents (U.S.)
• Aier (China)
• Zibo Kangbe (China)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.